Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-12 | Initiator Pharma | Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of PharmacologyInitiator Pharma A/S, a clinical-stage biotech company, today announced that an article titled “A novel reuptake inhibitor induces erection by increasing central dopamine and peripheral nitric oxide release” was published in the prestigious peer-reviewed scientific journal British Journal of Pharmacology. “We are very encouraged about the publication in such a well-known scientific journal. We have already demonstrated statistically significant and clinically relevant efficacy with pudanfensine in ED-related endpoints in a multi-centre phase IIb study, and this publication is another scientific validation of the mechanism of action and strengthens our believe in pudafensine as a novel treatment for patients who do not respond to or do not tolerate the currently marketed drugs,” said Claus Elsborg Olesen, CEO at Initiator Pharma The publication in the British Journal of Pharmacology describes the discoveries that pudafensine (IP2015), Initiator Pharma’s most advanced candidate drug, is a monoamine reuptake inhibitor that induces erection by increasing dopamine. Dopamine activate dopamine D2 receptors in the brain initiating erection, while the increase in dopamine in erectile tissue leads to activation of dopaminergic receptors relaxing erectile tissue by nitric oxide release. The unique mechanism of action of pudafensine contributes to initiate erection and to maintain erection. Moreover, the effects of pudafensine are even more significant in combination with a phosphodiesterase type 5 (PDE5) inhibitor, e.g., sildenafil. ”The scientific work underlying the discoveries is a result of strong collaborative effort, and the publication in the British Journal of Pharmacology is a recognition of novelty and solid scientific work,” said Professor Ulf Simonsen, CSO at Initiator Pharma and the senior author of the publication. Pudafensine (formerly IP2015) is in clinical development for both organic erectile dysfunction and neuropathic pain. Within the indication of erectile dysfunction, pudafensine has showed positive results in patients with erectile dysfunction in a phase IIa study, and demonstrated statistically significant and clinically relevant efficacy in ED-related endpoints, with no observations of critical adverse events, in a multi-centre phase IIb study conducted by MAC Clinical Research in 120 otherwise healthy organic erectile dysfunction patients. Erectile dysfunction is expected to affect 320 million men in 2025. The standard of care is treatment with PDE5 inhibitors, but the treatment is insufficient in 40 percent of the patients. Currently, there is no oral medication for the treatment of patients with erectile dysfunction who have insufficient effects or cannot tolerate PDE5 inhibitors (Munk et al., 2019). Initiator Pharma has developed a solid dosis of pudafensine allowing oral administration. The preclinical data suggest that pudafensine can either be dosed alone or in combination with a PDE5 inhibitor and hence provide a perspective for treating patients with insufficient effect or lack of tolerance to PDE5 inhibitors. References https://bpspubs.onlinelibrary.wiley.com/toc/14765381/0/0 Comerma-Steffensen S, Kun A, Prat-Duran J, Mogensen S, Albayrak EA, Fais R, Munro G, Peters D, Simonsen U. A novel reuptake inhibitor induces erection by increasing central dopamine and peripheral nitric oxide release. Br. J. Pharmacol. 2024, DOI: 10.1111/bph.16362 Munk NE, Knudsen J, Comerma-Steffensen S, Simonsen U. Systematic review of oral combination therapy for erectile dysfunction when phosphodiesterase type 5 inhibitor monotherapy fails. Sex Med Rev. 2019 Jan 30. pii: S2050-0521(18)30144-6. doi: 10.1016/j.sxmr.2018.11.007. |
||||
2024-04-12 | Initiator Pharma | Initiator Pharmas prekliniska farmakologiska resultat med pudafensine publiceras i British Journal of Pharmacology | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-26 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Initiator Pharma - Carnegie Investment Bank - 26 feb 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-23 | Redeye | Redeye: Initiator Pharma - Q4 2023 – Breathing optimism | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-23 | Initiator Pharma | INITIATOR PHARMA: BOKSLUTSKOMMUNIKÉ 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-23 | Initiator Pharma | INITIATOR PHARMA: YEAR END REPORT 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Initiator Pharma | MAC Clinical Research konverterar sin fordran till aktier i Initiator Pharma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Initiator Pharma | MAC Clinical Research converts its receivable into shares in Initiator Pharma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-23 | Initiator Pharma | Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-23 | Initiator Pharma | Nyemission och riktat aktieåterköp samt försäljning av aktier i samband med det långsiktiga incitamentsprogrammet för 2021 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-08 | Initiator Pharma | Initiator Pharma utvidgar sin position till en bredare franchise inom sexuell hälsa och intensifierar affärsutvecklingsarbetet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-08 | Initiator Pharma | Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-13 | Penser Access | Penser Access: Positiv utveckling - mer på agendan i år - Initiator Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-11-10 | Redeye | Redeye: Initiator Pharma Q3 - A historical quarter | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-10 | Initiator Pharma | INITIATOR PHARMA: RAPPORT FÖR TREDJE KVARTALET 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-10 | Initiator Pharma | INITIATOR PHARMA: Q3 2023 REPORT | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Initiator Pharma | Initiator Pharma presenterar på BioStock Life Science Summit den 25 oktober | Pressreleaser | Visa Stäng |
|
||||
2023-10-10 | Redeye | Redeye: Initiator Pharma - Positive Phase IIb results | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-09 | Penser Access | Penser Access: Levererar positiva resultat - Initiator Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-10-09 | Penser Access | Penser Access: Interview with Initiator Pharma - Erik Penser Bank - Oct 9th 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-10-06 | Initiator Pharma | Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-06 | Initiator Pharma | Initiator Pharma rapporterar positiva, statistiskt signifikanta och kliniskt relevanta fas IIb-effektdata för pudafensine | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-25 | Initiator Pharma | Utnyttjande i Initiator Pharmas incitamentsprogram LTI2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-25 | Initiator Pharma | Result of incentive program LTI2023 in Initiator Pharma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-22 | Penser Access | Penser Access: Interview with Initiator Pharma - Erik Penser Bank - Sep 21st 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-09-19 | Initiator Pharma | Initiator Pharma announces indication expansion – clinical drug candidates active in models of female sexual dysfunction | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-19 | Initiator Pharma | Initiator Pharma meddelar indikationsutvidgning av båda sina kliniska läkemedelskandidater till kvinnor med sexuell dysfunktion | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-25 | Redeye | Redeye: Initiator Pharma Q2 2023 - Development progres | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-25 | Initiator Pharma | INITIATOR PHARMA: RAPPORT FÖR ANDRA KVARTALET 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-25 | Initiator Pharma | INITIATOR PHARMA: Q2 2023 REPORT | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-09 | Initiator Pharma | Initiator Pharma obtains IP2018 patent in Europe for treatment of Erectile Dysfunction and Depression | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-09 | Initiator Pharma | Initiator Pharma erhåller patent i Europa för IP2018 mot erektil dysfunktion och depression | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-18 | Initiator Pharma | Initiator Pharma announces positive results from pudafensine Phase I pharmacokinetic trial | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-18 | Initiator Pharma | Initiator Pharma meddelar positiva resultat från farmakokinetisk fas I-studie med pudafensin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-05 | Initiator Pharma | Slutförande av aktieåterköpsprogram i Initiator Pharma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-05 | Initiator Pharma | Finalization of share buyback program in Initiator Pharma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Initiator Pharma | Initiator Pharma completes recruitment in Phase IIb trial with pudafensine (IP2015) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Initiator Pharma | Initiator Pharma slutför rekryteringen i fas IIb-studie med pudafensine (IP2015) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-21 | Initiator Pharma | Emission av nya aktier, återköp och försäljning av aktier i samband med långsiktigt incitamentsprogram för 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-21 | Initiator Pharma | Issuance of new shares, share buyback and sale of shares in connection with long term incentive program for 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-14 | Penser Access | Penser Access: Positiva resultat stärker caset - Initiator Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-06-05 | Initiator Pharma | Initiator Pharma reports dose-dependent significant efficacy of IP2018 in the placebo-controlled Phase IIa clinical trial of Erectile Dysfunction | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-05 | Initiator Pharma | Initiator Pharma rapporterar positiva dosberoende och signifikanta effektdata i den kliniska fas IIa-studien med IP2018 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-31 | Initiator Pharma | BioStock Life Science Spring Summit med Initiator Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-05-31 | Initiator Pharma | BioStock Life Science Spring Summit with Initiator Pharma | Pressreleaser | Visa Stäng |
|
||||
2023-05-30 | Initiator Pharma | Initiator Pharma erhåller det internationella generiska namnet pudafensine för IP2015 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-30 | Initiator Pharma | Initiator Pharma’s IP2015 obtains the International Nonproprietary Name pudafensine | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-26 | Initiator Pharma | Initiator Pharma A/S - Resolutions of the annual general meeting 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Redeye | Redeye: Initiator Pharma Q1 report - Countdown to readouts | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Initiator Pharma | INITIATOR PHARMA: RAPPORT FÖR FÖRSTA KVARTALET 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Initiator Pharma | INITIATOR PHARMA: Q1 2023 REPORT | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Initiator Pharma | Initiator Pharma A/S | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-02 | Initiator Pharma | Annual report and Remuneration report 2022 for Initiator Pharma A/S | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-02 | Initiator Pharma | Årsredovisning och ersättningsrapport 2022 för Initiator Pharma A/S | Rapporter | Ladda ner | Visa Stäng |
|